Sumitomo Pharma Co.,Ltd. [4506.T]
TOKYO, May 13 (Pulse News Wire) – Sumitomo Pharma CO.,LTD. (4506.T) reported robust financial results for the fiscal year ending March 2026, with revenue increasing 13.7% to ¥5.4 billion compared to the previous year.
Operating profit surged 145.4% to ¥910 million, driven primarily by higher sales volumes and cost efficiencies. The company's net income attributable to shareholders rose 352.2%, reaching ¥770 million, reflecting strong performance across its key segments. Core operating income saw significant growth, up 14.8% to ¥850 million, despite increased research and development expenses of 16%.
Sumitomo Pharma also highlighted its ongoing pipeline advancements, including DSP2085, a novel compound targeting Parkinson’s disease tremors, and enzomenib, a drug designed to inhibit menin-KMT2A protein interactions in acute myeloid leukemia patients. Both drugs have received orphan drug designations and fast-track approvals from regulatory bodies globally. The company continues to invest heavily in research and development, aiming to capitalize on emerging opportunities in oncology and regenerative medicine.
With a solid financial foundation and promising product pipelines, Sumitomo Pharma remains optimistic about future growth prospects.
🟢 Confidence: High AI-translated content.